Literature DB >> 18609680

Primary sclerosing cholangitis--what is the difference between east and west?

Ali Shorbagi1, Yusuf Bayraktar.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic, progressive, cholestatic liver disease characterized by inflammation and fibrotic obliteration of the hepatic biliary tree. It is commonly associated with inflammatory bowel disease (IBD). A number of complications can occur which require special consideration, the most important of which is the development of cholangiocellular carcinoma (CCC). Unfortunately, no medical therapy is currently available for the underlying liver disease. Liver transplantation is an effective, life-extending option for patients with advanced PSC. Geographical variations between East and West include a second peak for age with a lower association with IBD in a Japanese population and female predominance in a lone study from Turkey. The clinical and biochemical Mayo criteria may not be universally applicable, as different patients show variations regarding the initial presentation and natural course of the disease. Directing research towards explaining these geographical differences and understanding the pathogenesis of PSC is required in order to develop better therapies for this devastating disease.

Entities:  

Mesh:

Year:  2008        PMID: 18609680      PMCID: PMC2725335          DOI: 10.3748/wjg.14.3974

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  61 in total

1.  [Guidelines for the diagnosis and therapy of primary sclerosing cholangitis. Guidelines of the American College of Gastroenterology 2002].

Authors:  Y M Lee; M M Kaplan; Liana Gheorghe
Journal:  Rom J Gastroenterol       Date:  2002-12

2.  Association of primary sclerosing cholangitis with HLA-DRw52a?

Authors:  N Grunnet; H H Rasmussen; U Tage-Jensen; S Nørby Rasmussen
Journal:  Tissue Antigens       Date:  1991-09

3.  The prevalence of inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Necla Osmanoğlu; Fatih Tekin; Omer Ozütemiz; Galip Ersöz; Oktay Tekeşin
Journal:  Turk J Gastroenterol       Date:  2005-12       Impact factor: 1.852

4.  A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease.

Authors:  P Ricci; T M Therneau; M Malinchoc; J T Benson; J L Petz; G B Klintmalm; J S Crippin; R H Wiesner; J L Steers; J Rakela; T E Starzl; E R Dickson
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

5.  Pretransplant prediction of prognosis after liver transplantation in primary sclerosing cholangitis using a Cox regression model.

Authors:  J Neuberger; B Gunson; P Komolmit; M H Davies; E Christensen
Journal:  Hepatology       Date:  1999-05       Impact factor: 17.425

6.  Primary sclerosing cholangitis: findings on cholangiography and pancreatography.

Authors:  R L MacCarty; N F LaRusso; R H Wiesner; J Ludwig
Journal:  Radiology       Date:  1983-10       Impact factor: 11.105

7.  Primary sclerosing cholangitis in Japan--analysis of 192 cases.

Authors:  H Takikawa; T Manabe
Journal:  J Gastroenterol       Date:  1997-02       Impact factor: 7.527

8.  MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease).

Authors:  A J Grant; P F Lalor; S G Hübscher; M Briskin; D H Adams
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

9.  The survival benefit of liver transplantation.

Authors:  Robert M Merion; Douglas E Schaubel; Dawn M Dykstra; Richard B Freeman; Friedrich K Port; Robert A Wolfe
Journal:  Am J Transplant       Date:  2005-02       Impact factor: 8.086

10.  Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1.

Authors:  Xuesong Yang; Susan N Cullen; Jin H Li; Roger W Chapman; Derek P Jewell
Journal:  J Hepatol       Date:  2004-03       Impact factor: 25.083

View more
  13 in total

1.  Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis.

Authors:  James H Tabibian; Felicity Enders; Mohamad H Imam; Gururaj Kolar; Keith D Lindor; Jayant A Talwalkar
Journal:  Ann Hepatol       Date:  2014 May-Jun       Impact factor: 2.400

Review 2.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 3.  Epidemiology and clinical course of Crohn's disease: results from observational studies.

Authors:  Øistein Hovde; Bjørn A Moum
Journal:  World J Gastroenterol       Date:  2012-04-21       Impact factor: 5.742

4.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

Review 5.  Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.

Authors:  Bjarte Fosby; Tom H Karlsen; Espen Melum
Journal:  World J Gastroenterol       Date:  2012-01-07       Impact factor: 5.742

Review 6.  Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity?

Authors:  Takahiro Nakazawa; Itaru Naitoh; Kazuki Hayashi; Hitoshi Sano; Katsuyuki Miyabe; Shuya Shimizu; Takashi Joh
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

7.  Successful low-dose azathioprine for myasthenia gravis despite hepatopathy from primary sclerosing cholangitis: a case report.

Authors:  Josef Finsterer; Sonja Höflich
Journal:  J Med Case Rep       Date:  2010-11-08

Review 8.  Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.

Authors:  Carolina Palmela; Farhad Peerani; Daniel Castaneda; Joana Torres; Steven H Itzkowitz
Journal:  Gut Liver       Date:  2018-01-15       Impact factor: 4.519

Review 9.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

10.  Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran.

Authors:  Ahmad Khosravi Khorashad; Mohammad Khajedaluee; Elham Mokhtari Amirmajdi; Ali Bahari; Mohammad Reza Farzanehfar; Mitra Ahadi; Siavash Abedini; Mohammad Reza Abdollahi; Rosita Vakili; Hassan Vossoughi Nia
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.